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Abstract
Background: Relationships between inflammatory bowel disease and lactose containing foods remain controversial and
poorly defined regarding symptoms, nutritional outcomes, and epidemiologic associations for lactose maldigestion.
Methods: A literature review was performed using Pub Med, Cochrane library and individual references, to extract data
on lactose maldigestion prevalence in inflammatory bowel diseases. A meta-analysis was done using selected articles, to
determine odds ratios of maldigestion. Information was collected about symptoms, impact on pattern of dairy food
consumption, as well as the effects of dairy foods on the course of inflammatory bowel diseases.
Results: A total of 1022 articles were evaluated, 35 articles were retained and 5 studies were added from review articles.
Of these 17 were included in meta-analysis which showed overall increased lactose maldigestion in both diseases.
However increased risk on sub analysis was only found in Crohn’s in patients with small bowel involvement. Nine
additional studies were reviewed for symptoms, with variable outcomes due to confounding between lactose intolerance
and lactose maldigestion. Fourteen studies were evaluated for dairy food effects. There was a suggestion that dairy foods
may protect against inflammatory bowel disease. Nutritional consequences of dairy restrictions might impact adversely
on bone and colonic complications.
Conclusions: Lactose maldigestion in inflammatory bowel disease is dependent on ethnic makeup of the population
and usually not disease. No bias of increased disease prevalence was noted between lactase genotypes. Intolerance
symptoms depend on several parameters besides lactose maldigestion. Dairy foods may decrease risks of inflammatory
bowel disease. Dairy restrictions may adversely affect disease outcome.
Keywords: Lactose malabsorption, Intolerance, Inflammatory Bowel Diseases
Introduction
The Inflammatory Bowel Diseases (IBD), Crohn’s Disease
(CD) and Ulcerative Colitis (UC), are complex conditions
with enigmatic causes. Pathogenesis implicates interac-
tions between a genetically susceptible host and a dis-
turbed bacterial microflora resulting in aberrant innate
and adaptive immune responses [1]. The intestinal micro-
flora is responsive to various factors such as antibiotics
and diet [2, 3]. In IBD, diet may be important both for
pathogenesis and nutrition [4–6], although specific proof
is lacking for the former [7].
The role of dairy foods (DFs) in IBD has been contro-
versial and confounded by the phenotypic divide of lac-
tase status in the adult population. About 1/3 of adults
retain the ability to digest lactose (LP; lactase persist-
ence, lactose digesters) while the rest lose it (LNP; lac-
tase non -persistence, lactose maldigesters [LM]). The
links between lactose, milk, DFs and IBD are topics re-
lated on several levels. The world segregation into LP
/LNP correlates with a number of diseases, including
IBD, raising the question of a coincidental event or an
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evolutionary modifier of disease similar to latitudinal
distributions [8]. As such, unequal phenotype distribu-
tions of LP/LNP in IBD may be an additional risk factors
for IBD [9] or may predispose to LM. Patients with IBD
may find that DFs aggravate their symptoms, leading
them and some professionals to recommend a reduced
lactose diet [10]. In healthy persons milk and other DF
avoidance is partly related to true lactose intolerance
(LI) or the presumption of LI due to suggestive symp-
toms [11, 12]. However symptoms from diet are also
affected by consumption of Fermentable Oligo, Di,
Monosaccharide And Polyols (FODMAPs) in IBD [13, 14].
Lactose is generally excluded in a low FODMAP diet
independent of lactose digestion status.
It also remains unclear what role DF avoidance has on
nutritional effects on patients with IBD. This systematic
review seeks primarily to determine the prevalence of
LM in IBD and establish whether there is a bias toward
either phenotype. Secondary outcomes were determining
whether symptoms of LI play a role in DF avoidance,
and whether DF restriction impacts on IBD course.
Methods
Search strategy
A review of the literature between Jan 1965 to June 2016
was undertaken. The search engines Medline (Pub Med)
and Cochrane Library were used to obtain relevant articles.
Terms used were lactose maldigestion or lactose intoler-
ance or milk intolerance or lactose sensitivity (LI with sys-
temic symptoms) AND Inflammatory Bowel Disease or
Crohn’s disease or Ulcerative colitis. In the case of the
Cochrane library, the terms “systematic review” or “meta-
analysis” were also selected, to narrow the search. Two
authors (AS and PG) independently evaluated articles for
inclusion in meta-analysis and disagreement was settled by
consensus. A second search for articles was also included
with the terms nutritional benefits OR detriments of milk
OR dairy products in Inflammatory Bowel Disease, Chrohn’
disease Or Ulcerative colitis. References of individual review
articles were also screened for relevant publications.
Definitions
For the purpose of meta-analysis a clear distinction was
made between objective tests of LM vs. symptoms attrib-
uted to LI or sensitivity. The reasons for this are that LI
is subjective and can occur in the absence of LM and
symptoms elicited during lactose challenge tests do not
necessarily reflect reactions to DF ingestion. The term
lactose tolerance test (LTT) retains the name but an ab-
normal test suggests LM and LI may occur as with the
hydrogen breath test (BT). Small bowel biopsies, urinary
sugar tests or genetic tests define the propensity for LM
but do not predict symptomatic LI.
Article eligibility for meta-analysis or nutritional effects
Original articles and case reports (including more than 5
patients) were included if patients underwent objective
testing for lactose digestion (regardless of method), and
if they were compared to a healthy control group. Ab-
stracts in English were included if sufficient data were
available from the report. Articles including patients
with other diseases but no IBD were excluded from ana-
lyses. For the second outcome, looking at prevalence of
symptoms of LI in IBD, articles referring to LI, or DF in-
tolerance or sensitivity were also sought, regardless of
formal testing for lactose digestion. For nutritional im-
pact, studies investigating DF effects or general diet on
IBD were sought. The latter had to include reference to
milk or DFs. Additional references were manually ex-
tracted from review articles on the topic.
Data extraction for meta-analysis
Year of publication, country of origin, number of pa-
tients and controls, type of test for LM, test outcomes,
distribution of CD or UC cases, site of involvement in
CD, disease activity at time of testing, and surgical his-
tory were recorded from each study. A description of
genetic likelihood of LM for patients versus controls was
estimated. Each study included in the meta-analysis was
graded by country for low (= grade 1, ≤20 % LNP), mod-
erate (= grade 2, 21 –79 % LNP), or high risk (=grade 3,
LNP ≥80 %), based on classification as per Mishkin [15]
and Szilagyi [9].
Quality assessment
Articles included in the meta-analysis were graded based
on the Newcastle Ottawa scale for case control studies
[16]. In this scheme, high quality studies achieved a
score of 5 or more, and scores of 4 or less were consid-
ered low quality. Abstracts were not graded. PRISMA
guidelines were followed [17].
Data analysis
For each study, two by two tables of LM status (LM vs.
not-LM) and IBD status (IBD vs. healthy control) were
obtained. For studies with a zero cell, a continuity cor-
rection of 0.5 was used [18]. The association between
LM and IBD were assessed using odds ratios (OR) and
the corresponding 95 % confidence intervals (CIs). An
OR greater than 1.0 indicates an increased risk of LM
among IBD group compared with the healthy control
group. The statistical significance of the summary OR
was determined with the Z test, and a p-value less than
0.05 was considered statistically significant.
The heterogeneity among studies was determined by
the Cochran Q statistics, where a p-value greater than
0.05 indicates a lack of heterogeneity. The I 2 statistics
were also presented [19]. For the qualitative interpretation
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of heterogeneity, I 2 values of at least 50 % are usually con-
sidered to represent substantial heterogeneity, while
values of at least 75 % indicate considerable heterogeneity
according to the Cochrane Handbook. The summary OR
was obtained using a fixed-effect model (Mantel-Haenszel
method) when there was a lack of heterogeneity (I 2 ≤ 50 %),
or a random-effects model (the DerSimonian and Laird
method) when otherwise [20, 21]. The potential publication
bias was estimated by a funnel plot for the overall analysis.
Egger’s linear regression test on the natural logarithm scale
of the OR was used to assess the funnel plot asymmetry; the
significance was set at the p < 0.05 [22].
Sensitivity analysis was performed according to the fol-
lowing subgroups: type of IBD (CD or UC), specific dis-
ease site in the case of CD (SB-small bowel only, TiC-
Terminal ileum and Colon, DC-colon only); type of test
(BT-Breath Hydrogen measurement, LTT-Lactose toler-
ance test, urinary sugar ratios and small bowel biopsies);
and finally evaluation of LM among the low risk group.
The purpose of analyzing low risk group separately was
that any disease effect involving intestinal lactase levels
would be more likely to be detected in this group. All
analyses were performed using SAS statistical package,
version 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
The first search yielded a total of 570, while the comple-
mentary search yielded an additional 452 publications
during the specified time period. Of the combined 1022
articles, 35 studies were retained, as per inclusion/exclu-
sion criteria. Seventeen of these were included in the
meta-analysis of prevalence of LM. Nine of 35 additional
papers without controls, discussion of methodology or
DF related symptoms were included for narrative review.
Nine of 35 studies were included in a review of nutri-
tional effects of DFs. A further 5 were added to these 9
after manual extraction from general diet review articles
in IBD for a total of 40 papers (Fig. 1).
Prevalence of lactose maldigestion in IBD
Description of included studies for meta-analysis
The meta-analysis included a total of 1935 IBD patients
(560 CD, 614 UC) and 761 controls. Table 1 outlines
demographics of 17 studies (23 - 38). The mean age of
participants based on available data was 35.6 years for
CD, 40.8 years for UC, and 37.7 years for controls. One
study focused exclusively on a pediatric population
(mean age 13.5, range of 5–18) [30]. Based on reports
that specified gender distribution, there were more
females in the IBD groups than the control group.
Eleven studies originated from countries with low risk for
LNP [15, 23–32] and 4 specified ethnic make-up [15, 27,
30, 31]. Five reports were from moderate risk countries
[33–37] and 1 was from a high risk country [38].
Twelve studies used a lactose challenge with measure-
ment of BT [15, 24–27, 30, 33–38]. One of these also
analyzed the C/T-13910 polymorphisms [24]. Two stud-
ies used LTT alone [31, 32]. Two evaluated jejunal biop-
sies [23, 28] and one used urinary lactose/L-arabinose
sugar ratio to define LM [29]. Intestinal biopsies [39],
BT and the LTT have been validated against genetic tests
for the north European C/T- 13910 lactase polymor-
phisms [40].
Outcome of meta-analyses
The OR for LM in IBD vs. in controls including the 4
indirect tests was 1.61 (95 % CI: 1.00–2.57), p = 0.048.
Heterogeneity was substantial at I2 = 69.3 %. In subgroup
analyses, for CD specifically the outcome was still statis-
tically significant with an OR of 2.29 (95 % CI:1.09–4.80,
p = 0.03, I2 = 74.8 %), but did not reach statistical signifi-
cance for UC (OR = 1.14, 95 % CI:0.69–1.86, p = 0.62,
I2 = 53.8 %). Fig. 2 shows the forest plots with log OR
using all type of tests.
Subgroup analysis using BT alone showed similarly
that LM was only significant in CD (OR = 2.35, 95 %
Fig. 1 The outline for flow of retrieved articles
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Table 1 Studies of lactose maldigestion in IBD using breath test, lactose tolerance test, jejunal biopsies or urinary sugar ratio tests
Author (reference) County Activity of disease Test Method Age (female %) CD N/ LM Age (female %) UC N/ LM Age (female %) Control
N / LM
NOS Score
Gupta [33] India I BT 34.7 (26)a 27 / 10a 36.2 18 / 10a 36.2 (26)a 45 / 12 7
Eadala [24] Wales UK Ic BT Gen 19–86 (38) 70d / 2b 20–81 (44) 95 / 11b 21–56 (15) 30 / 0 8
Barrett [25] Australia Ic BT 40 (56) 92d / 39 40 (44) 56 / 22 34 (20) 71 / 13 9
Banos Madrid [34] Spain nd BT nd 18 / 3 nd 24 / 4 nd 25 / 5 7
Ginard [35] Spain nd BT Quest nd nd 40 (32) 52 / 13 41 (20) 34 / 11 7
Von Turpitz [26] Germany 24A 25Ic BT Bx 39.9 (30) 49 / 16 nd nd 43.1 (11) 24 / 5 6
Mishkin [15] Canadaf Ic BT 36.9 (62) 121d / 70 37 (71) 139 / 65 nd nd 158 / 46 8
Bernstein [27] Canadaf 18A 11I BT Quest nd nd 39 (13) 29 / 13 41 (4) 14 / 5 8
Kochlar [36] India 22A 38I BT nd nd 36.7 (35) 60 / 25 36.4 (7) 20 / 8 7
Ogata [38] Japan nd BT LTT nd 32/29BT32/30LTT nd nd nd 51/26BT51/37LTT nd
Park [28] Scotland 21A 41I Bx 40 (38) 62d nd nd 40 (9) 13 5
Lobely [29] England nd USR 42 nd 16 42 (nd) 6 28.5 (13) 40 6
Pironi [37] Italy Ic BT 33 (23) 37 / 18 nd nd 35 (36) 67 / 11 7
Kirschner [30] United Statesf 37Ag 33I of IBD BT 13.5 (nd) 50 / 17 13.5 (nd) 20 / 5 nd (nd) 42 7
Pena [23] England 37A 35I Bx nd nd nd 72 / 9 nd 21 / 2 6
Tandon [31] United Statesf nd LTT nd nd nd 70e [51/12] [19/16] nd 94e [53/11] [41/29] 7
Chalfin [32] United States nd LTT 40.8 (2) 5 / 3 42.8 (5) 9 / 4 44.3 (7) 12 5
BT breath hydrogen test, LTT lactose tolerance test, Bx jejunal biopsy, USR urinary sugar ratio(lactose/L-arabinose), Gen Genetic test for north European lactase polymorphism C/T-13910, Quest questionnaire, LM lactose
maldigestion, LA lactose absorption, nd-not done or not stated, I inactive disease, A active disease
aGupta reported LM % and gender distribution in IBD vs Control
bEadala reported breath tests in the bracketted space and genetic test results in the primary listed numbers, CC is the genotype for lactase non persitence from the C/T-13910 north European polymorphism
cIncluded information on previous surgery in Crohn’s disease. Mishkin reported no effect of surgery on LM. In these reports only Eadala reported a single patient after colectomy for ulcerative colitis
dStudies which included enough data on site of disease in CD and frequency of lactose maldigestion
eThis study evaluated Jewish and non Jewish patients and controls
fStudies specifying ethnic make-up of patients and controls























Fig. 2 a Forest plot of 17 articles which evaluated indirect tests of lactose maldigestion in patients with inflammatory bowel diseases compared
with controls. The 4 indirect tests were the hydrogen breath test, lactose tolerance test proximal small bowel biopsy and sugar urinary ratio test.
b Forest plot of 11 studies evaluating only Crohn’s disease using all type of tests. c Forest plot of 11 studies evaluating only ulcerative colitis using all
type of tests
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CI:1.21–4.57, p = 0.012, I2 = 74.1 %), but not in UC
(OR = 1.21, 95 % CI:0.67 – 2.18, p = 0.53, I 2 = 59.8 %).
Fig. 3 shows the forest plots with log OR using breath
test only. LTT did not show any statistically significant
differences in CD (n = 2 studies, OR = 1.0 (95 %
CI:0.03–33.3)) or UC (n = 2 studies, OR = 0.84 (95 %
CI:0.46–1.54)) [data not shown].
Sub-analysis of CD sites were analyzed in relation to
SB, TiC or Colon. When all populations were included,
site impact was not significant [SB: OR = 2.53(95 % CI:
0.45 – 14.3); TiC: OR = 1.42 (95 % CI:0.35 – 5.83);
Colon: OR = 1.42 (95 % CI:0.82 – 2.46)], based on 5
studies [15, 24, 25, 28, 30]. However, when low risk pop-
ulations were analyzed independently, SB and TiC sites
were significantly associated with LM whereas Colon
was not [SB: OR = 6.2 (95 % CI:1.01 – 35.1), p = 0.039,
I2 = 65.3 %; TiC: OR = 4.2 (95 % CI:2.26 – 7.66), p <
0.0001, I 2 = 49.1 %; Colon: OR = 1.01 (95 % CI:0.49 –
2.06), p = 0.307, I2 = 16.8 %] [15, 24, 25, 28] (Fig. 4).
The effect of disease activity on LM status was conflict-
ing, with some studies showing an effect [23, 26, 36], while
another showed no effect in either UC nor CD [30]. Surgi-
cal history was not found to affect LM status in CD [15].
No publication bias was detected for the combination of
all tests in IBD (p = 0.91), or individual papers on CD (p =
0.89) or UC (p = 0.37) using Egger’s test. No publication
bias was detected for low-risk group CD tests (p = 0.51).
Description of studies not included in meta-analysis
There were a total of 9 studies of LM or LI that were ex-
cluded from the meta- analysis because no specific con-
trols were provided. Outcomes were compared to
nationally recognized frequency of LNP status or they
described other aspects of tests [41–49]. Wiecke et al.
examined jejunal biopsies from 65 children [mean age
14 range 3–18 years] with a number of gastrointestinal
diseases and found low lactase levels in IBD, however
these similar to national expectations [30–35 % LNP]
[41]. In a large number of patients who underwent BT,
Huppe et al. found the frequency of LM in 124 CD pa-
tients to be comparable with population data, but failed
to explore effects of site, disease activity or resection ex-
tent on LI/LM. In 53 UC patients LM rates were signifi-
cantly lower [3.8 % vs about 20 % of the German
population] [42]. This finding was also reported by Mis-
hkin et al. [15]. In a double-blind crossover study of 39
UC patients, BT outcomes were similar to Mexican
population rates [46 % vs about 50 –70 %] [43]. In 2
studies from Denmark, (national LM prevalence, 5–6 %),
performance of an LTT showed no difference from ex-
pected rates [6 % CD, 9 % UC] [44, 45]. However one re-
ported higher LM rates with activity of IBD [44], while the
other found no relationship other than ethnic distribution
in UC patients [45]. Nevertheless a lactose free diet





Fig. 3 a Forest plot of 8 studies evaluating only Crohn’s disease using breath test. b Forest plot of 8 studies evaluating only Ulcerative colitis
using breath test
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Three other studies were identified. In one, concentra-
tions of urinary lactose/raffinose were increased in 19 %
of CD patients but no other specific details were given
[46]. Two, studies reported outcomes of jejunal biopsies.
Dunne et al. reported that small bowel concentrations of
lactase and brush border surface were reduced in pa-
tients with CD, while levels in UC were comparable to
controls [47], This was confirmed in another study of
UC patients [48]. One study addressed symptoms only
but these were not lactose related [49].
Milk and lactose intolerance and lactose sensitivity
Thirteen studies (excluding those dealing with nutrition
because they describe different aspects) alluded to symp-
toms of milk or lactose intolerance [MI and LI respect-
ively], [24, 26, 27, 30, 31, 33–37, 42, 44, 49]. In 7 of
these, the terms LI and LM were interchangeable sug-
gesting that symptoms during testing might reflect daily
LI [27, 30, 31, 33, 34, 36, 42]. In 4 studies LI was used to
define LM [27, 34, 36, 42]. LI and LM were more fre-
quent in pancolitis than in left-sided colitis or proctitis,
and more with disease activity [36]. LI occurred more
frequently with small bowel CD or higher loads of lac-
tose [37]. In 2 studies, MI was higher in CD [26] or UC
[27] than in controls. However the rate of MI correlated
with duration of disease rather than location, or resec-
tion length in CD [26].
Dissociation between LI and LM was noted in 5 stud-
ies [24, 26, 27, 33, 37]. In particular Eadala et al. noted a
discrepancy between the frequency of genetic LNP in
patients and controls compared with the prevalence of
lactose sensitivity which reached 70 % in IBD [24]. They
also noted a discrepancy between the results of genetic
tests and BT, with positive BT tests occurring more fre-
quently in patients. This observation was also noted by
Barrett et al. [25], where ileal disease produced more fre-
quent positive tests than ileocolic or colonic involve-
ment. Pironi et al. recorded more frequent LM in
operated CD compared with controls yet LI occurred in
only 3 of 11 patients with operations [37].
Articles dealing with nutritional impact of dairy foods
A total of 14 articles were reviewed primarily for nutri-
tional effects [50–63]. Descriptions of these publications
are presented in Table 2. Two were epidemiological,
showing a rise in incidence of IBD correlating with ris-
ing consumption of western type diet, particularly ani-
mal protein including DFs [50, 51]. In 2 cross sectional
studies, consumption of 1.25 L of milk /week was bene-
ficial in reducing symptoms in UC [52] while milk and




Fig. 4 Forest plots of studies which divided Crohn’s disease patients by site of dominant disease using any test and including patients only from
low risk for lactase non persistent status compared with healthy controls. Figure a, represents analysis of small bowel only, Figure b represents
analysis of terminal ileum and colon, Figure c represents colon only
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Table 2 Studies reporting on the impact of dairy foods on inflammatory bowel diseases (IBD). DF = dairy food, Inc = incidence
Author Type of Study Crohn’s Disease (N) Ulcerative Colitis (N) IBD (N) Healthy Control (N) Outcome
Kitahora [50] Epidemiology - 10819 - - Positive correlate. with UC inc
Shoda [51] Epidemiology 292 - - - Inc high correlate with DF in univariate analysis
Magee [52] Prospective
Cross-section
- 81 - - 1250 ml/week protective
Octoratou [53] Prospective Cohort 28 new 30chronic - - 38 Milk and yogurt protective
Abubakar [54] Case-control 218 - - 812 Drinking pasteurized milk protects
Opstelten [55] Cohort 110 244 - 401,326 DF protect CD 0.3 CI (0.13–0.65) UC diagnose
>3 years Significant trend 0.04
Spehlmann [59] Twin Study - - 512 Twins 1 with disease 207 and (392 non twin IBD) DFs no effect
Jantchou [57] Prospective Cohort 33 43 - 67504 DF no effect. Animal protein + correlate
Reif [58] Case-control 33 54 - 144 Pre Disease no effect of lactose
Jowetta [56] Prospective Cohort - 183 (52 % relapse) - - No effect 1.17 CI 0.53–2.5 Medium intake no
effect with high intake
Joachim [60] Prospective Cross-section 33 27 - - DFs prominent in relapse
Jowett [61] Prospective Cohort - 183 (52 % relapse) - - 68 % diet thought important, most restricted DFs
Vernia [63] Case–control 91 96 - 420 and (276 other diseases) Females with CD and UC had significantly lower
Ca intake than recommended
Brazil Lopes [62] Cross Section 21 44 - - 64.7 % restricted DFs









prospective study suggested that pasteurized milk re-
duced risk for CD [54]. The most recent and largest pro-
spective cohort study supported the observation that the
highest quartile of milk intake significantly reduced CD
risk. There was also an overall significant trend for reduced
UC if data were analyzed 3 years after commencement of
the study [55]. Four studies with different methodologies
evaluating DFs among a general diet in IBD, did not find
any statistically significant impact [56–59]. Four studies
used questionnaires with different intended outcomes re-
garding role of DFs in IBD. One reported increased flares
with DFs [60], while 3 reported reduced intake of milk and
DFs [61–63]. In the report by Jowett restrictions were sup-
ported by professional advice [61] while symptomatic, ac-
tive IBD patients were more likely to withhold DFs in
another study [62].
From papers reviewed for lactose maldigestion, Gupta
et al. found that despite similar rates of LM, IBD pa-
tients restricted DFs [33]. Bernstein et al. noted that DF
restriction by UC patients or physician advice was based
solely on presence of disease [27]. Finally in a large study
of CD patients, it was argued that a high fat content in
DFs is likely the source of symptoms [49]. Self-reported
LI and active disease were the most important patient
reported reasons for DF restriction [24, 49, 62, 63].
Dietary advice included a milk free diet in UC, regard-
less of LM status [44]. Two suggested.
DF restriction with disease activity only [26, 36]. Five
suggested to restrict if positive LM status is established
[23, 28, 35, 41, 48], while 4 suggested that there was no
need to restrict DFs in IBD at all [24, 27, 37, 49].
Discussion
Relationships between IBD and DF suggest that rates of
LM largely reflect ethnic backgrounds of patients. Activ-
ity of IBD and small bowel involvement in CD increases
LM rates. Symptoms of LI during tests may not reflect
daily DF reactions. Consequences of true or self per-
ceived LI may impact on DF consumption which may
have variable outcomes.
Lactose maldigestion in IBD
In the mid 20th century, milk protein allergy was consid-
ered a possible cause of UC [64]. As well in the early
1960s reports emerged showing that intestinal lactase
levels were diminished in UC and were accompanied by
self-restricted and physician-advised reduction of DFs in
IBD [65, 66]. The impact of ethnicity was not yet proven.
The meta-analysis on LM rates does show a statisti-
cally significant increase in prevalence. However, analysis
of CD and UC independently reveals that the outcome is
driven by CD with small bowel CD involvement. Sub
analysis of BT also follows the overall pattern suggesting
that LM is either secondary to mucosal disease, motility
disorder or bacterial overgrowth not necessarily genetics
[67]. In other cases ethnic distributions account for the
frequency of LM. These results should be interpreted
with some caution in light of moderate or high hetero-
geneity encountered.
The notion that IBD rates differ between LP and LNP
populations rests on epidemiological correlations be-
tween IBD and population distributions of LP and LNP
[8]. The outcome of the meta-analysis suggests that LP
and LNP persons may be equally affected by IBD.
There are only few studies examining possible risks of
different lactase alleles in IBD. Eadala et al. evaluated C/
T-13910 polymorphism in a group of patients from
Wales and found a 6 % rate of CC (LNP) genotype
among 165 Welsh IBD patients [24]. This frequency is
close to the national rate. Earlier reports were conflicting
however. Buning et al. did not find any statistically sig-
nificant differences in frequency of IBD among German
patients with CC genotype [68]. Elguezabal et al. could
not confirm increased TT/CT genotypes in Spanish pa-
tients [69]. However an earlier study from Spain [70] and
one from New Zealand [71] did find increased prevalence
of Crohn’s disease in TTgenotype (LP phenotype) persons.
The current observations however can’t rule out differ-
ent rates or delay in disease development between LP
and LNP. For example IBD rates are different between
Indigenous populations and Caucasians described both
in Canada [72] and New Zealand [73]. In both areas In-
digenous people are predominantly LNP and Caucasians
are predominantly LP.
Symptoms of LI
It is no longer accurate to equate LI with LM. The reason
for this is that studies of LI in patients with irritable bowel
syndrome (IBS) showed similar frequency of symptoms
whether they were LNP or LP phenotype [74, 75]. Another
reason is the ability of LNP persons to adapt to continued
lactose consumption [76]. Lactose in LNP/LI persons in-
duces symptoms (LI) through a metabolic effect on the
microbiome [77]. In LNP persons, continued ingestion of
sufficient lactose will lead to microbiome adaptation
resulting in altered metabolomes as well as reduced test
outcomes for BT [78].
However ability to adapt to lactose in IBD is unclear
and there are no formal trials. Using lactulose, a disac-
charide with similar properties to lactose failed to show
adaptation compared with healthy controls [79]. Pironi
et al. however may have detected microbial adaptation
since despite increased LM status only 8 % of CD pa-
tients were also LI [37].
There are two other factors which may alter symptoms
to lactose/DFs. As in the case of the study by Nolan –Clark,
DFs containing fats may actually be the prime cause of
symptoms [49], a possibility also stressed by Mishkin [12].
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As well, a role of FODMAPs driving food sensitivities needs
to be considered [80]. Restriction of these may reduce
symptoms in IBD [81], since irritable bowel syndrome is
frequent in IBD even in remission [82]. However, in this
paradigm, genetics of lactase may not play a role. In studies
reviewed, LI and LM were interchanged in several studies
[27, 30, 31, 33, 34, 36, 42] and Eadala introduced the con-
cept of lactose sensitivity [24]. They reported the highest
symptom rate of any study, independent of genetic analysis
and with discrepant outcomes with BTs [24]. The reasons
for these observations aren’t clear and the study was criti-
cized on methodological grounds [83]. This review in the
end doesn’t allow a true estimate of the frequency of LI in
IBD patients. Activity of disease, site in CD and surgical re-
sections variably affected outcome. The overall impression
is that self reported LI along with counseling led to DF con-
sumption restrictions.
Health related effects of lactose/dairy foods in IBD
Specific impact of milk and DFs consumption on IBD
has not been studied as extensively as on other diseases
(reviewed in [84]). In general there are 3 topics to con-
sider: first is the relationship of DFs to risk of IBD, sec-
ond DFs impact on IBD relapse rates, finally possible
risks of dietary DFs restrictions.
While 2 epidemiological studies [50, 51] suggested a
positive correlation of increasing DFs intake with in-
creasing incidence of IBD, remaining studies suggested
possible protection by DFs [52–55] or no effect on IBD
[56–59]. Further studies are needed to verify protective
outcomes. However there is a hint that an ecological fal-
lacy type relationship between DFs and IBD exists. In
this situation, observed ecological relationships between
disease and target variables are opposite to those ex-
pected at patient level studies. A similar paradigm oc-
curs between DFs and colorectal cancer [8, 85].
The second topic that DFs aggravate established IBD is
not clear. One study reported that milk and DFs intake
were associated with flares [60] and this is supported in a
study of food groups in patients with UC [86]. However in
a large review, of effects of general diets in IBD, no convin-
cing evidence was found to show that any nutrient induced
flares [7]. The presence of IBS and role of FODMAPs con-
tributing to symptoms may cloud the issue [82].
The third topic is whether DF restriction has any
negative impacts. In the general population, an NIH
conference on LI concluded that the main health hazard
is the improper withdrawal of DFs. Benefits from DFs
were stressed [87]. Among these, bone health, better
control of hypertension [88], weight gain [89, 90] and a
reduced risk for colorectal cancer either through calcium
or vitamin D is oberved [91].
In IBD, osteopenia and osteoporosis are consequences
of chronic inflammation and medications [92–94]. The
role of calcium and DF intake in IBD-related bone dis-
ease is unclear [95–97] or controversial [98] but intui-
tively is still important.
Colorectal cancer is increased in IBD colitis and may
be linked with chronic inflammation also [99]. Calcium
and vitamin D may be protective both for cancer [100,
101] and provide anti-inflammatory effects [102].
Risks of cardiovascular complications may be in-
creased in IBD [103] and calcium may contribute by re-
ducing arterial stiffness [88]. Evaluation of the specific
impact of DFs in IBD require further evaluation.
There are limitations to this review. Conclusions from
meta-analyses are as accurate as the papers reviewed. Al-
though the quality of most studies was rated as adequate,
the period spans 50 years with the majority of studies be-
ing older. The period of study includes 4 modalities of lac-
tase assessment and conceptual changes in the genetics of
lactase as well as concepts related to symptoms. These
variations, as well as inclusion of different populations,
and the few number of studies may well account for het-
erogeneity. However, in the studies reviewed for meta-
analysis patients were always studied in parallel with
healthy controls, and the outcome sought was an objective
prevalence of LM in IBD regardless of method of ascer-
tainment. To our knowledge, this is the only review to
date which derives conclusions based on the available
literature.
Summary and conclusions
It is suggested that LM in IBD is determined by ethnicity
in most cases of UC and CD. In CD small bowel involve-
ment can produce secondary LM in LP. Although un-
proven, activity may also impact on LM. LM can
aggravate LI but self reported LI or the overlap with
FODMAP confound DFs specific role. Moreover there is
emerging suggestive evidence that DFs may have bene-
fits in IBD and restriction may impact unfavorably. Fur-
ther work is needed to evaluate the role of DFs in IBD
as well on methods to avoid their restriction.
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